The USA and Japan are the countries where the
markets for drugs to treat illnesses of the stomach and intestines are the
largest. The US market accounts for over 15% of global sales and Japan for just
under 10% of these medications by value. Their growth rates, however, at about
4.5% and 4% respectively per annum, are surpassed by those of China and India
at 6.4% and 7.7%. China's is the only market which combines a large share of
the total market and rapid growth: it is worth $4.2 billion or nearly 8% of the
global total which is worth approaching $60 billion a year. Despite fierce
competition and the presence of large numbers of producers of generic drugs,
this probably makes China a particularly attractive market for gastrointestinal
drug manufacturers.
The gastrointestinal diseases drugs market covers medicines used for the
treatment of ulcerative colitis, diverticular disease, perianal infections,
anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key
gastrointestinal drugs include anti-peptic agents (antacids, antagonists,
proton pump inhibitors, sucralfate, and misoprostol), antiemetics, adsorbents,
anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants,
hyperosmotic, saline, and stimulant/irritants.
Many of these drugs can be bought without prescription in pharmacies or
supermarkets and convenience stores. This widespread availability and often low
unit price are factors that boost sales in poor areas of rich countries like
the USA, where many other drugs are very high in price and in China, with its
still low, though growing, GDP per capita.
The market
for gastrointestinal drugs is quite fragmented, with
above 70% shared among the many small companies outside the leading 7 and only
one company, Japan's Takeda Pharmaceuticals, having an market share that
approaches 10%. The second and third largest companies in the market are
Allergan of the USA and the Danish Novo Nordisk, each with shares a little over
5% of the total.
One of the trends shaping the market is a development of cost-effective new
medications to treat gastrointestinal diseases. Drug manufacturing companies
are offering biosimilars for the treatment of gastrointestinal diseases. Over
the last decade, biologics have gained an important place for treatment of
moderate to severe Inflammatory Bowel Disease (IBD). However, the treatment
cost has gone up with the use of the biologics. Biosimilars are copy versions
of approved original biological medicines whose patents have expired. The use
of biosimilars is cost-effective and can reduce the price per mg from 25% to
40%. For example, CT-P13 (Remsima, Inflectra), a biosimilar of infliximab
(Remicade) was approved by European Medicines Agency (EMA) in 2013 and by the
Food and Drug Administration (FDA) in 2016. This drug is being widely used to
treat inflammatory bowel disease (IBD).
The gastrointestinal disorders drugs market is slowing shifting to the usage of
biologics as opposed to treatment with traditional drugs for some indications.
This market report excludes biologics used for treating these disorders.
Markets Covered: Antacids,
Antiulcerants, Vitamin And Minerals, Antiobesity Drugs, Antiemetics And
Antinauseants, Antidiarrhoeals
Companies Mentioned: AbbVie, Johnson
& Johnson, Takeda Pharmaceticals, Allergan, and UCB
Countries: Brazil, China, France,
Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western
Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and
forecast.
Data: Ratios of market size and
growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal
Disorders Drugs Indicators Comparison.
Data segmentations: country and
regional historic and forecast data, market share of competitors, market
segments.
Sourcing and Referencing: Data and
analysis throughout the report is sourced using end notes.
About The Business
Research Company.
The Business Research Company is a Business Intelligence Company
which excels in company, market and consumer research. It has offices in the
UK, the US and India and a network of trained researchers in 15 countries
globally.
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
